The NHS wastes billions on “me too” drugs that confer little or no added therapeutic benefit. James Moon and colleagues propose a way to restructure healthcare prescribing to get better value for money and persuade drug companies to invest in developing innovative drugs
No takes yet. Share an insight, caveat, or question.
Moon et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: